Free Trial

Centrica (LON:CNA) Announces Quarterly Earnings Results

Centrica logo with Utilities background

Key Points

  • Centrica reported quarterly earnings of GBX 7 ($0.09) per share, with a return on equity of 25.16% and a net margin of 5.39%.
  • Insider Chris O'Shea sold 770,946 shares valued at approximately £1.3 million, while insider Philippe Boisseau purchased 1,016 shares for £1,686.56.
  • Citigroup maintained a "buy" rating on Centrica's shares following the earnings announcement.
  • Five stocks to consider instead of Centrica.
  • Limited Time Offer: Unlock powerful research tools, advanced financial data, and expert insights to help you invest with confidence. Save 50% when you upgrade to MarketBeat All Access during the month of July. Claim your discount here.

Centrica (LON:CNA - Get Free Report) announced its quarterly earnings data on Thursday. The integrated energy company reported GBX 7 ($0.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Centrica had a return on equity of 25.16% and a net margin of 5.39%.

Centrica Price Performance

CNA opened at GBX 162.75 ($2.19) on Friday. The stock has a fifty day moving average of GBX 160.18 and a 200-day moving average of GBX 150.05. The firm has a market capitalization of £8.13 billion, a P/E ratio of 7.76, a PEG ratio of 0.45 and a beta of 1.08. Centrica has a 12-month low of GBX 112.99 ($1.52) and a 12-month high of GBX 168.90 ($2.27). The company has a quick ratio of 0.40, a current ratio of 1.77 and a debt-to-equity ratio of 66.48.

Insiders Place Their Bets

In other news, insider Chris O’Shea sold 770,946 shares of the stock in a transaction on Monday, June 23rd. The stock was sold at an average price of GBX 168 ($2.26), for a total value of £1,295,189.28 ($1,740,611.85). Also, insider Philippe Boisseau bought 1,016 shares of Centrica stock in a transaction dated Wednesday, June 25th. The stock was acquired at an average price of GBX 166 ($2.23) per share, with a total value of £1,686.56 ($2,266.58). Insiders bought 4,494 shares of company stock valued at $718,408 in the last 90 days. Corporate insiders own 0.20% of the company's stock.

Analysts Set New Price Targets

Separately, Citigroup reiterated a "buy" rating on shares of Centrica in a research report on Friday.

View Our Latest Report on CNA

Centrica Company Profile

(Get Free Report)

Centrica is energising a greener, fairer future for our colleagues, customers and communities. Our integrated business operates across the energy value chain, with over ten million Retail customers, leading brands such as British Gas and Bord Gáis Energy, and the UK's largest energy services workforce.

Recommended Stories

Earnings History for Centrica (LON:CNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Centrica Right Now?

Before you consider Centrica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centrica wasn't on the list.

While Centrica currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines